Lakefront Biotherapeutics NV (BSP:LKFT34) Cyclically Adjusted FCF per Share: R$0.31 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:LKFT34 Lakefront Biotherapeutics NV BSP:LKFT34
14 GF Score
Price R$6.61
GF Value R$33.32
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lakefront Biotherapeutics NV Cyclically Adjusted FCF per Share?

Lakefront Biotherapeutics NV BSP:LKFT34 14 Cyclically Adjusted FCF per Share is R$0.31 as of Mar. 2026. GuruFocus rates BSP:LKFT34 with a GF Score™ of 14/100 and a GF Value™ of R$33.32 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Lakefront Biotherapeutics NV's adjusted free cash flow per share for the three months ended in Mar. 2026 was R$-0.380. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is R$0.31 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Lakefront Biotherapeutics NV's average Cyclically Adjusted FCF Growth Rate was -45.50% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -20.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -24.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Lakefront Biotherapeutics NV was -20.00% per year. The lowest was -28.60% per year. And the median was -27.50% per year.

As of today (2026-08-09), Lakefront Biotherapeutics NV's current stock price is R$6.61. Lakefront Biotherapeutics NV's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was R$0.31. Lakefront Biotherapeutics NV's Cyclically Adjusted Price-to-FCF of today is 21.32.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Lakefront Biotherapeutics NV was 25.87. The lowest was 7.73. And the median was 12.08.


Lakefront Biotherapeutics NV  (BSP:LKFT34) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Lakefront Biotherapeutics NV's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=6.61/0.31
=21.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Lakefront Biotherapeutics NV was 25.87. The lowest was 7.73. And the median was 12.08.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Lakefront Biotherapeutics NV Cyclically Adjusted FCF per Share Related Terms


Lakefront Biotherapeutics NV Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Lakefront Biotherapeutics NV's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakefront Biotherapeutics NV Cyclically Adjusted FCF per Share Chart

Lakefront Biotherapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.56 0.94 0.70 0.57 0.62

Lakefront Biotherapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.60 0.58 0.62 0.31

BSP:LKFT34 vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Lakefront Biotherapeutics NV's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lakefront Biotherapeutics NV Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Lakefront Biotherapeutics NV's Cyclically Adjusted Price-to-FCF falls into.


BSP:LKFT34
14GF Score
Lakefront Biotherapeutics NV BSP:LKFT34
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakefront Biotherapeutics NV Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lakefront Biotherapeutics NV's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.38/136.5600*136.5600
=-0.380

Current CPI (Mar. 2026) = 136.5600.

Lakefront Biotherapeutics NV Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.093 102.267 -0.124
201609 -0.103 102.118 -0.138
201612 0.131 102.614 0.174
201703 -0.086 103.972 -0.113
201706 -0.110 103.902 -0.145
201709 -0.133 104.170 -0.174
201712 -0.250 104.804 -0.326
201803 -0.164 105.419 -0.212
201806 -0.228 106.063 -0.294
201809 -0.026 106.618 -0.033
201812 -0.226 107.252 -0.288
201903 -0.298 107.876 -0.377
201906 -0.299 107.896 -0.378
201909 13.088 107.470 16.631
201912 -0.487 108.065 -0.615
202003 -0.325 108.550 -0.409
202006 -0.687 108.540 -0.864
202009 -0.975 108.441 -1.228
202012 -0.397 108.511 -0.500
202103 -0.652 109.522 -0.813
202106 -0.431 110.305 -0.534
202109 -0.722 111.543 -0.884
202112 -0.909 114.705 -1.082
202203 -0.295 118.620 -0.340
202206 -0.607 120.948 -0.685
202209 -0.507 124.120 -0.558
202212 -0.861 126.578 -0.929
202303 -0.417 126.528 -0.450
202306 -0.520 125.973 -0.564
202309 -0.484 127.083 -0.520
202312 -0.305 128.292 -0.325
202403 -0.529 130.552 -0.553
202406 -0.585 130.691 -0.611
202409 -0.353 130.968 -0.368
202412 -0.316 132.346 -0.326
202503 -0.207 134.348 -0.210
202506 -0.547 133.495 -0.560
202509 -0.313 133.740 -0.320
202512 -0.238 135.070 -0.241
202603 -0.380 136.560 -0.380

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of R$0.31 mean?
Lakefront Biotherapeutics NV (BSP:LKFT34) has a Cyclically Adjusted FCF per Share of R$0.31 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Lakefront Biotherapeutics NV and its competitors.
Is Lakefront Biotherapeutics NV's Cyclically Adjusted FCF per Share too high?
Lakefront Biotherapeutics NV's current Cyclically Adjusted FCF per Share is R$0.31. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 14/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Lakefront Biotherapeutics NV's Cyclically Adjusted FCF per Share of R$0.31 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Lakefront Biotherapeutics NV and its competitors. Lakefront Biotherapeutics NV's current Cyclically Adjusted FCF per Share is R$0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Based on GuruFocus' analysis, Lakefront Biotherapeutics NV (BSP:LKFT34) is currently considered Possible Value Trap. The stock's GF Value™ is R$33.32, compared to a current price of R$6.61 — trading 80.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is R$0.31. Lakefront Biotherapeutics NV's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (BSP:LKFT34), the current Cyclically Adjusted FCF per Share is R$0.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lakefront Biotherapeutics NV (BSP:LKFT34) Overvalued in 2026?

Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued. The current stock price of R$6.61 is trading 80.2% below its estimated GF Value™ of R$33.32. GuruFocus considers Lakefront Biotherapeutics NV to be Possible Value Trap.

Key valuation signals for BSP:LKFT34:

  • Cyclically Adjusted FCF per Share: R$0.31
  • GF Value™: R$33.32 vs. price of R$6.61 (80.2% below fair value)
  • GF Score™: 14/100 with 4 warning signs

No single metric tells the full story. See the BSP:LKFT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lakefront Biotherapeutics NV Business Description

Address Schalienhoevedreef 20 T, Mechelen, BEL, 2800
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
14GF Score

Get the complete analysis for BSP:LKFT34

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$6.61
Price
R$33.32
GF Value